Does Moderate Physical Activity in Hemodialysis Patients Reduce Inflammation?
The purpose of this study is to observe a potential benefit of moderate physical activity by using bed mounted cycles during hemodialysis treatment sessions on inflammatory markers in the blood of patients with end-stage renal disease (ESRD).
|Study Design:||Observational Model: Case-Crossover
Time Perspective: Prospective
|Official Title:||Does Moderate Physical Activity in Chronic Hemodialysis Patients Reduce Inflammation Via Inhibition of Proinflammatory Monocyte Activity?|
- Composition of monocyte subpopulations as defined by CD14 and CD16 expression [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Serum CRP values [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Dialysis quality (kt/V, URR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Serum and DNA samples
|Study Start Date:||January 2010|
|Study Completion Date:||December 2011|
|Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
chronic hemodialysis patients with elevated inflammation markers
Behavioral: moderate physical activity
bed mounted cycles for physical activity for 30 min during each hemodialysis session
Patients with ESRD on chronic hemodialysis patients frequently have elevated markers of inflammation (e.g., serum CRP values) and accumulation of proinflammatory monocyte populations in the circulation. The level of inflammation is highly predictive for cardiovascular disease and mortality. Physical activity has been shown to improve dialysis efficacy by improving the elimination of retention solutes. In healthy individuals, sports activity influences inflammatory immune parameters. The study will observe the influence of moderate physical activity (using a bed mounted cycle for 30min during dialysis thrice weekly) on circulating monocyte subpopulations and inflammatory proteins over a 9 month period in 16 chronic hemodialysis patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00893165
|Department of Internal Medicine II|
|Halle(Saale), Sachsen-Anhalt, Germany, D06120|
|Study Director:||Matthias Girndt, MD||Martin-Luther-University Halle-Wittenberg, Germany|